Wednesday, May 29, 2013

Beijing Vigoo Biologics EV71 Vaccine for Enterovirus 71 shows positive data in Phase III trials

Subsidiary of China national biotech group - Beijing Vigoo Biological has announced that its Enterovirus 71 vaccine was effective in up to 90% of test subjects. The company carried out a large Phase III trial in 10,245 children, aged 6 to 35 months. Half were randomized to receive vaccine. EV71, which strikes mainly children under the age of five, is a major cause of hand, foot and mouth disease. 


Enter your email address:


Delivered by FeedBurner